» Articles » PMID: 33028957

The Tissue Proteome in the Multi-omic Landscape of Kidney Disease

Overview
Journal Nat Rev Nephrol
Specialty Nephrology
Date 2020 Oct 8
PMID 33028957
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Kidney research is entering an era of 'big data' and molecular omics data can provide comprehensive insights into the molecular footprints of cells. In contrast to transcriptomics, proteomics and metabolomics generate data that relate more directly to the pathological symptoms and clinical parameters observed in patients. Owing to its complexity, the proteome still holds many secrets, but has great potential for the identification of drug targets. Proteomics can provide information about protein synthesis, modification and degradation, as well as insight into the physical interactions between proteins, and between proteins and other biomolecules. Thus far, proteomics in nephrology has largely focused on the discovery and validation of biomarkers, but the systematic analysis of the nephroproteome can offer substantial additional insights, including the discovery of mechanisms that trigger and propagate kidney disease. Moreover, proteome acquisition might provide a diagnostic tool that complements the assessment of a kidney biopsy sample by a pathologist. Such applications are becoming increasingly feasible with the development of high-throughput and high-coverage technologies, such as versatile mass spectrometry-based techniques and protein arrays, and encourage further proteomics research in nephrology.

Citing Articles

Decoding Kidney Pathophysiology: Omics-Driven Approaches in Precision Medicine.

Delrue C, Speeckaert M J Pers Med. 2024; 14(12).

PMID: 39728069 PMC: 11679258. DOI: 10.3390/jpm14121157.


Unveiling the role of transgelin as a prognostic and therapeutic target in kidney fibrosis via a proteomic approach.

Kwon S, Cheon S, Kim K, Seo A, Bae E, Lee J Exp Mol Med. 2024; 56(10):2296-2308.

PMID: 39375532 PMC: 11542076. DOI: 10.1038/s12276-024-01319-7.


Integrated multi-omics with machine learning to uncover the intricacies of kidney disease.

Liu X, Shi J, Jiao Y, An J, Tian J, Yang Y Brief Bioinform. 2024; 25(5).

PMID: 39082652 PMC: 11289682. DOI: 10.1093/bib/bbae364.


Minimal Change Disease: Pathogenetic Insights from Glomerular Proteomics.

Barar A, Pralea I, Maslyennikov Y, Munteanu R, Berindan-Neagoe I, Pirlog R Int J Mol Sci. 2024; 25(11).

PMID: 38891801 PMC: 11171934. DOI: 10.3390/ijms25115613.


Gene regulatory networks in disease and ageing.

Unger Avila P, Padvitski T, Leote A, Chen H, Saez-Rodriguez J, Kann M Nat Rev Nephrol. 2024; 20(9):616-633.

PMID: 38867109 DOI: 10.1038/s41581-024-00849-7.


References
1.
Lindenmeyer M, Kretzler M . Renal biopsy-driven molecular target identification in glomerular disease. Pflugers Arch. 2017; 469(7-8):1021-1028. DOI: 10.1007/s00424-017-2006-y. View

2.
Kiryluk K, Bomback A, Cheng Y, Xu K, Camara P, Rabadan R . Precision Medicine for Acute Kidney Injury (AKI): Redefining AKI by Agnostic Kidney Tissue Interrogation and Genetics. Semin Nephrol. 2018; 38(1):40-51. PMC: 5753434. DOI: 10.1016/j.semnephrol.2017.09.006. View

3.
Saez-Rodriguez J, Rinschen M, Floege J, Kramann R . Big science and big data in nephrology. Kidney Int. 2019; 95(6):1326-1337. DOI: 10.1016/j.kint.2018.11.048. View

4.
Smith L, Kelleher N . Proteoform: a single term describing protein complexity. Nat Methods. 2013; 10(3):186-7. PMC: 4114032. DOI: 10.1038/nmeth.2369. View

5.
Liu Y, Beyer A, Aebersold R . On the Dependency of Cellular Protein Levels on mRNA Abundance. Cell. 2016; 165(3):535-50. DOI: 10.1016/j.cell.2016.03.014. View